Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
1992-11-6
pubmed:abstractText
Streptokinase (SK), which activates human plasminogen by promoting its conversion to plasmin, is normally obtained from beta-hemolytic streptococci. Treatment with SK is an effective therapy for improving survival and preserving left ventricular function after coronary thrombosis. We report the cloning, expression in E. coli to levels of 25% of the total cell protein, and characterization of a novel SK (SKC-2) gene, the product of which is functionally equivalent to the naturally-derived protein. The availability of a recombinant streptokinase (rSK) in high yield and purity offers a potentially attractive alternative source of this important therapeutic agent.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
B
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0733-222X
pubmed:author
pubmed:issnType
Print
pubmed:volume
10
pubmed:geneSymbol
SKC-2
pubmed:owner
NLM
pubmed:authorsComplete
N
pubmed:pagination
1138-42
pubmed:dateRevised
2000-12-18
pubmed:meshHeading
pubmed:year
1992
pubmed:articleTitle
High level expression of streptokinase in Escherichia coli.
pubmed:affiliation
Mammalian Cell Genetics Division, Centro de Ingeniería Genética y Biotecnología, Havana, Cuba.
pubmed:publicationType
Journal Article